🔍

SENORES - Senores Pharma.

📊 NSE: SENORES 🏢 Pharmaceuticals - Indian - Formulations 📅 Last Updated: 12/14/2025 13:00

📢 Recent Corporate Announcements

Senores Pharmaceuticals Promoters Confirm No Share Encumbrance for FY 2025-26

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 22 Apr 2026, 05:25 PM

Senores Pharmaceuticals has submitted its annual disclosure under SEBI Takeover Regulations for the financial year ending March 31, 2026. The promoter, Mr. Swapnil Jatinbhai Shah, confirmed on behalf of the promoter group that no shares were encumbered, directly or indirectly, during the period. This filing is a mandatory compliance requirement ensuring transparency regarding promoter shareholding status. It indicates that the promoter's stake remains free of any new pledges or liens, which is a positive indicator of financial stability.

Annual disclosure submitted under Regulation 31(4) of SEBI (SAST) Regulations, 2011
Promoter group confirms zero new encumbrances on company shares for the FY ended March 31, 2026
Disclosure covers the promoter, promoter group, and persons acting in concert (PAC)
The filing was submitted to BSE and NSE on April 02, 2026, following the close of the financial year

💡 This is a routine regulatory filing confirming that promoter shares are not pledged. No immediate action is required as this reflects standard corporate governance.

Senores Pharmaceuticals to Close Trading Window from April 1, 2026 for FY26 Results

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 27 Mar 2026, 12:01 PM

Senores Pharmaceuticals Limited has notified the exchanges that its trading window will be closed starting April 1, 2026. This closure is mandatory under SEBI's insider trading regulations ahead of the company's financial results for the quarter and year ending March 31, 2026. The restriction applies to all designated persons, including directors and promoters. The window will reopen 48 hours after the audited financial results are officially declared to the public.

Trading window closure effective from April 1, 2026
Applies to the audited financial results for the quarter and year ending March 31, 2026
Window to reopen 48 hours post-result declaration
Mandatory compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015

💡 This is a standard regulatory procedure with no direct impact on stock value. Investors should monitor for the upcoming board meeting date announcement to assess the company's annual financial performance.

Senores Pharma Appoints Jatin Gajjar as CTO; R&D President Manohar Lalge Resigns

🟡 NEUTRAL ⭐ 6/10

MANAGEMENT 📅 17 Mar 2026, 04:39 PM

Senores Pharmaceuticals has announced a leadership transition effective March 17, 2026. Mr. Jatin Gajjar, a veteran with over 30 years of experience in the pharmaceutical sector, has been appointed as the Chief Technology Officer (CTO) and designated as Senior Management Personnel. Concurrently, Mr. Manohar Lalge has resigned from his role as President of Research and Development. The new CTO brings extensive experience from major industry players like Sun Pharma, Zydus Cadila, and Amneal Pharmaceuticals.

Mr. Jatin Gajjar appointed as Chief Technology Officer and Senior Management Personnel effective March 17, 2026.
Mr. Manohar Lalge resigned as President – Research and Development effective close of business hours on March 17, 2026.
New CTO Jatin Gajjar possesses over 30 years of leadership experience in manufacturing operations and product development.
The appointment was approved by the Board of Directors via circular resolution on March 17, 2026.

💡 Investors should monitor the transition in the R&D department to ensure there is no disruption in the company's product pipeline or regulatory filing timelines. The addition of an experienced CTO from top-tier pharma companies is a positive sign for operational execution.

Senores Pharmaceuticals Appoints Jatin Gajjar as CTO; R&D Head Manohar Lalge Resigns

🟡 NEUTRAL ⭐ 6/10

MANAGEMENT 📅 17 Mar 2026, 04:39 PM

Senores Pharmaceuticals has announced a leadership transition with the appointment of Mr. Jatin Gajjar as Chief Technology Officer (CTO) and Senior Management Personnel, effective March 17, 2026. Mr. Gajjar brings over 30 years of experience from top-tier firms like Sun Pharma and Zydus Cadila, specializing in complex formulations and injectables. Concurrently, Mr. Manohar Lalge has resigned from his role as President of Research and Development. This change reflects a strategic shift in managing the company's R&D and technological innovation pipeline.

Mr. Jatin Gajjar appointed as Chief Technology Officer (CTO) effective March 17, 2026.
Mr. Gajjar has over 30 years of experience in pharma technology, manufacturing, and product development.
Outgoing President of R&D, Mr. Manohar Lalge, resigned effective close of business on March 17, 2026.
New CTO has previous leadership experience at global majors including Sun Pharma, Amneal, and Zydus Cadila.

💡 Investors should watch for any shifts in R&D focus or delays in product filings during this leadership transition. The appointment of a veteran with 30+ years of experience is a positive sign for the company's technical execution.

Senores Pharmaceuticals to Host Group Analyst Meet on March 12, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 09 Mar 2026, 04:35 PM

Senores Pharmaceuticals Limited has scheduled a group meeting with analysts and institutional investors on March 12, 2026, at 11:00 AM IST. The meeting will be held physically at the company's corporate office in Ahmedabad, Gujarat. Management intends to discuss publicly available information and has clarified that no unpublished price sensitive information (UPSI) will be shared. This routine interaction is part of the company's investor relations engagement following its listing.

Group meeting with Analysts and Institutional Investors scheduled for March 12, 2026
Interaction to commence at 11:00 AM IST at the Ahmedabad corporate office
Discussions will be based strictly on publicly available information with no UPSI disclosure
Official intimation filed on March 09, 2026, under SEBI LODR Regulation 30(6)

💡 Investors should watch for any post-meeting presentations or transcripts uploaded to the exchange for insights into management's commentary on business growth. No immediate trading action is required as this is a routine disclosure.

Senores Pharma Issues $4.1 Million Corporate Guarantee for US Subsidiary

🟡 NEUTRAL ⭐ 4/10

ROUTINE 📅 03 Mar 2026, 03:06 PM

Senores Pharmaceuticals Limited has provided a corporate guarantee of up to USD 4,100,000 (approximately INR 34-35 crores) to HDFC Bank. This guarantee supports credit facilities for its wholly-owned US subsidiary, Senores Pharmaceuticals Inc. The agreement has a maximum tenure of 10 years and is conducted at arm's length. While this creates a contingent liability for the parent company, it facilitates capital access for its international operations.

Corporate guarantee issued for an amount up to USD 4,100,000
Guarantee provided to HDFC Bank for credit facilities of US-based wholly-owned subsidiary
Maximum tenure of the credit facilities and associated guarantee is 10 years
Transaction will be reflected as a contingent liability in the company's financial statements
Promoter interest is limited to directorships in the subsidiary, maintaining arm's length status

💡 Investors should monitor the growth and debt-servicing capability of the US subsidiary to ensure the guarantee is not invoked. No immediate action is required as this is a standard financial support structure for global subsidiaries.

Senores Pharma Issues $1.5M Corporate Guarantee for US Subsidiary Havix Group

🟡 NEUTRAL ⭐ 4/10

ROUTINE 📅 03 Mar 2026, 03:00 PM

Senores Pharmaceuticals has issued a corporate guarantee worth USD 1.5 million to HDFC Bank to secure additional credit facilities for its US-based material subsidiary, Havix Group Inc. (Aavis Pharmaceuticals). This guarantee is an extension of a previous arrangement from July 2025 and will remain valid for up to 10 years or until the credit facility is closed. While this adds to the parent company's contingent liabilities, it provides necessary financial support for the subsidiary's operations. The transaction is conducted at arm's length with no direct promoter interest beyond directorships.

Corporate guarantee issued for USD 1,500,000 to HDFC Bank Limited.
Beneficiary is Havix Group Inc. (Aavis Pharmaceuticals), a material subsidiary in the USA.
The maximum tenure for the credit facilities and the guarantee is 10 years.
The guarantee will be recorded as a contingent liability in the company's financial statements.
This is a follow-up to a previous credit facility intimation dated July 10, 2025.

💡 Investors should note the increase in contingent liabilities but recognize this as standard financial support for a material subsidiary. Monitor the subsidiary's operational performance to ensure it can service the debt independently.

Senores Pharmaceuticals to Host Group Investor Meeting on March 06, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 02 Mar 2026, 03:26 PM

Senores Pharmaceuticals Limited has scheduled a physical group meeting with analysts and institutional investors on March 06, 2026. The meeting is set to commence at 03:30 P.M. IST at the company's corporate office in Ahmedabad, Gujarat. Management has explicitly stated that discussions will be limited to publicly available information and no unpublished price sensitive information (UPSI) will be shared. This routine disclosure follows Regulation 30(6) of the SEBI Listing Obligations and Disclosure Requirements.

Group meeting with analysts and institutional investors scheduled for March 06, 2026.
The meeting will be held physically at the Ahmedabad corporate office starting at 03:30 P.M. IST.
Discussions will be strictly based on publicly available information to ensure compliance.
The schedule is subject to change based on exigencies from either the host or the company.

💡 Investors should watch for any investor presentations or meeting transcripts filed with the exchanges following the event for insights into management's outlook. No immediate trading action is required based on this routine scheduling notice.

Senores Pharmaceuticals Schedules Group Analyst and Investor Meet for March 06, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 02 Mar 2026, 03:21 PM

Senores Pharmaceuticals Limited has announced a group meeting with analysts and institutional investors scheduled for March 06, 2026. The meeting will be held physically at the company's corporate office in Ahmedabad, Gujarat, starting at 03:30 P.M. IST. The company clarified that discussions will be based strictly on publicly available information, ensuring no unpublished price sensitive information is shared. This is a standard regulatory disclosure under SEBI (LODR) Regulations to maintain transparency with the investment community.

Group meeting with analysts and institutional investors scheduled for March 06, 2026
The meeting will commence at 03:30 P.M. IST at the Ahmedabad corporate office
Discussions will be limited to publicly available information with no UPSI shared
Disclosure made in compliance with Regulation 30(6) of SEBI (LODR) Regulations, 2015

💡 No immediate action is required as this is a routine investor engagement. Investors may look for any subsequent investor presentations or transcripts for potential insights into the company's outlook.

Senores Pharma Clarifies Use of Funds from 11.7 Lakh Warrant Issue for Subsidiary Working Capital

🟡 NEUTRAL ⭐ 6/10

FUNDRAISE 📅 13 Feb 2026, 05:54 PM

Senores Pharmaceuticals has issued a clarification regarding its proposed preferential issue of 1,170,000 convertible equity warrants. The company specified that a portion of the funds raised will be utilized to provide loans to its 75%-owned subsidiary, Apnar Pharma Private Limited, to meet its working capital requirements. This follows the company's acquisition of the majority stake in Apnar Pharma in December 2025. The disclosure provides transparency on capital allocation following the upcoming Extra-Ordinary General Meeting.

Proposed issue and allotment of 11,70,000 convertible equity warrants via preferential issue.
Funds earmarked for granting loans to subsidiary Apnar Pharma Private Limited for working capital.
Company confirms 75% ownership of Apnar Pharma following an acquisition in December 2025.
Clarification issued as an amendment to the EGM notice dated January 07, 2026.

💡 Investors should monitor the successful completion of the warrant issue and the subsequent impact of the working capital infusion on Apnar Pharma's operational performance.

Senores Pharma Clarifies Preferential Issue of 11.7 Lakh Warrants at ₹812 Per Share

🟡 NEUTRAL ⭐ 7/10

FUNDRAISE 📅 04 Feb 2026, 03:25 PM

Senores Pharmaceuticals has issued a clarification regarding its upcoming preferential issue of 11,70,000 convertible equity warrants. The company has fixed the fair value for the conversion of these warrants at ₹812.00 per share, based on a valuation report by Maitri Valuation Private Limited. Although the issue is less than 5% of the post-issue capital, the company provided these details to comply with its Articles of Association. The valuation methodology assigned 100% weightage to the Market Approach as it yielded the highest floor price compared to Asset and Income approaches.

Proposed issue and allotment of 11,70,000 convertible equity warrants on a preferential basis.
Fair value for conversion of warrants determined at ₹812.00 per share.
Valuation methodology assigned 100% weightage to the Market Price Method.
The quantum of the proposed issue is less than 5% of the post-issue fully diluted share capital.
Independent valuation conducted by Maitri Valuation Private Limited as per company Articles of Association.

💡 Investors should monitor the upcoming Extra-Ordinary General Meeting results for formal approval of this fundraise. The pricing at ₹812 provides a benchmark for the company's internal valuation of its equity.

Senores Pharma Shareholders Approve 11.7 Lakh Convertible Warrants Issue to Promoters

🟢 POSITIVE ⭐ 7/10

FUNDRAISE 📅 31 Jan 2026, 04:22 PM

Senores Pharmaceuticals Limited has received shareholder approval for the issuance of 11,70,000 convertible equity warrants to the promoter group on a preferential basis. The special resolution was passed with a significant majority of 96.45% during the EGM held on January 31, 2026. Notably, while the resolution passed, 25.21% of institutional votes were cast against the proposal. This issuance represents a strategic capital infusion by the promoters, signaling long-term commitment to the company's growth.

Approved issuance of 11,70,000 convertible equity warrants to the Promoter and Promoter Group.
The special resolution was passed with 96.455% votes in favor and 3.545% against.
Public Institutions cast 6,42,044 votes (25.21% of their polled votes) against the resolution.
A total of 1,81,11,053 votes were polled during the EGM process.

💡 The promoter's decision to infuse capital via warrants is a positive signal of confidence; however, investors should monitor the specific pricing and use of proceeds. Keep an eye on the eventual conversion of these warrants into equity and its impact on EPS dilution.

Senores Pharma EGM Approves 11.70 Lakh Convertible Warrants to Promoters

🟢 POSITIVE ⭐ 7/10

FUNDRAISE 📅 31 Jan 2026, 03:23 PM

Senores Pharmaceuticals Limited held an Extra-Ordinary General Meeting (EGM) on January 31, 2026, to approve a significant fundraise. The company sought shareholder approval for the issuance of 11,70,000 convertible equity warrants on a preferential basis. These warrants are being issued specifically to the Promoter and Promoter Group category, indicating a capital infusion from the company's leadership. The resolution was presented as a special resolution, and the final voting results are expected to be submitted shortly.

Issuance of 11,70,000 convertible equity warrants approved via special resolution
Fundraise conducted through a preferential issue on a private placement basis
Warrants exclusively allocated to the Promoter and Promoter Group category
EGM held via Video Conferencing with 48 members in attendance
Remote e-voting was conducted between January 28 and January 30, 2026

💡 Investors should view the promoter-led capital infusion as a sign of confidence in the company's long-term growth. Monitor the official disclosure of the warrant conversion price to evaluate the potential equity dilution.

Senores Pharma Q3FY26 PAT Surges 85% YoY; ANDA Portfolio Quadruples to 46

🟢 POSITIVE ⭐ 9/10

EARNINGS 📅 27 Jan 2026, 06:17 PM

Senores Pharmaceuticals reported a robust Q3FY26 with consolidated revenue growing 64% YoY to ₹175 crores and PAT increasing 85% to ₹32 crores. The company's ANDA portfolio has expanded significantly from 12 to 46 approved products within a year, providing a strong pipeline for future launches. Management maintained its FY26 guidance of 50% revenue growth and 100% PAT growth, supported by the recent acquisition of Apnar Pharma. The India branded generics business also showed explosive growth, increasing six-fold during the quarter.

Consolidated EBITDA grew 86% YoY to ₹54 crores with margins expanding 360 bps to 30.9%
ANDA portfolio quadrupled to 46 approved products, with 28 approved ANDAs currently available for launch
Completed 75% acquisition of Apnar Pharma, targeting ₹120-150 crores revenue from this unit in FY27
India branded generics revenue grew 6x YoY to ₹10.5 crores in Q3FY26
9MFY26 PAT more than doubled YoY to ₹84 crores, tracking ahead of annual guidance

💡 Investors should view the strong execution and margin expansion positively, especially the rapid scaling of the ANDA portfolio and the strategic US acquisition. Monitor the integration of Apnar Pharma and the rollout of the 28 approved-but-unlaunched ANDAs as key growth drivers.

Senores Pharmaceuticals Releases Q3 & 9M FY26 Earnings Call Audio Recording

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 20 Jan 2026, 07:02 PM

Senores Pharmaceuticals Limited has officially released the audio recording of its earnings conference call for the quarter and nine months ended December 31, 2025. The call, conducted on January 20, 2026, featured participation from the Chairman, Managing Director, and CFO. This disclosure is a standard regulatory requirement under SEBI LODR Regulations to ensure all investors have access to management discussions. The recording is available on the company's website for public review.

Earnings conference call for Q3 and 9M FY26 was held on January 20, 2026.
Audio recording is now accessible via the company's investor relations weblink.
Top leadership including Chairman Sanjay Majmudar and MD Swapnil Shah represented the company.
The company confirmed that no Unpublished Price Sensitive Information (UPSI) was shared during the call.

💡 Investors should listen to the audio recording to understand management's perspective on the company's financial health and future outlook. No immediate action is required as this is a routine compliance filing.

View All SENORES Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Regulated Markets grew 86.9% YoY to INR 106.9 Cr in Q2 FY26; Emerging Markets declined 13.4% YoY to INR 31.7 Cr; Branded Generics grew 1337.3% YoY to INR 11.9 Cr; API segment declined 20.5% YoY to INR 2.9 Cr.

Geographic Revenue Split

Regulated Markets (US, Canada, UK) contributed 69.7% of Q2 FY26 revenue (INR 106.9 Cr); Emerging Markets contributed 20.7% (INR 31.7 Cr); Branded Generics (India) contributed 7.8% (INR 11.9 Cr).

Profitability Margins

Gross Margin improved to 64.7% in Q2 FY26 (up 1,230 bps YoY); EBITDA Margin reached 30.6% (up 750 bps YoY); PAT Margin stood at 18.6% (up 560 bps YoY).

EBITDA Margin

EBITDA Margin was 30.6% in Q2 FY26, a 750 bps increase from 23.1% in Q2 FY25, driven by a higher share of own ANDA product launches which carry 40-42% margins.

Capital Expenditure

Planned Capex of INR 107.0 Cr for a sterile injection manufacturing facility in Atlanta; INR 154.8 Cr allocated for inorganic growth and strategic initiatives.

Credit Rating & Borrowing

Company plans to use INR 73.1 Cr for full/partial repayment of borrowings and INR 20.2 Cr for subsidiary Havix's debt repayment. Specific interest rates not disclosed.

⚙️ Operational Drivers

Raw Materials

Not disclosed in available documents; COGS represented 37.2% of revenue in Q2 FY26 (INR 57.1 Cr).

Key Suppliers

Not disclosed in available documents; management notes dependence on a limited supplier base as a risk.

Capacity Expansion

US facility expanding from 1.2 billion units to 2 billion units; 3rd manufacturing line operational in Q3 FY26 and 4th line by end of FY26.

Raw Material Costs

Total COGS for H1 FY26 was INR 118.4 Cr, representing 39.5% of total income, compared to INR 82.5 Cr in H1 FY25.

Manufacturing Efficiency

Capacity utilization is being optimized through the addition of new manufacturing lines in the US to reach 2 billion units to support a 25%+ growth target.

📈 Strategic Growth

Expected Growth Rate

25%

Growth Strategy

Growth driven by 4 pillars: (i) Expansion of ANDA portfolio in Regulated Markets; (ii) Scale-up of CDMO/CMO segment; (iii) Portfolio expansion in Emerging Markets; and (iv) Scale-up of Branded Generics in India.

Products & Services

Pharmaceutical formulations including Tablets, Capsules, Sterile Injections, and Controlled Substances; also provides CDMO/CMO services and management consultancy.

Brand Portfolio

Senores, Havix, Ratnatris.

New Products/Services

Planned new product launches every quarter for the next 4-5 quarters; 86 new approvals received in Emerging Markets during Q2 FY26.

Market Expansion

Expanding US manufacturing footprint in Atlanta and increasing penetration in Emerging Markets through 86 new product approvals.

Strategic Alliances

Utilizes profit-share models with marketing partners for own ANDA products, supplemented by licensing fees and COGS reimbursement.

🌍 External Factors

Industry Trends

Industry involves a 5-year journey from development to commercialization; shift toward own ANDA launches is driving margin expansion from 35% toward 40-42% in regulated markets.

Competitive Landscape

Competes in the global generic and CDMO markets; management focuses on 'mid-tier standardized markets' to avoid high-competition segments.

Competitive Moat

Moat built on US-based manufacturing for controlled substances, a diversified business model (CDMO + Own Products), and a strong pipeline of 86+ new approvals.

Geopolitical Risks

Geographical concentration risk in the US market; regulatory changes in pharmaceutical standards could trigger litigation or product bans.

⚖️ Regulatory & Governance

Industry Regulations

Compliance with US FDA, Indian Accounting Standards (Ind AS), and Section 133 of the Companies Act, 2013.

Environmental Compliance

Subject to various environmental laws regarding prevention and control of pollution; specific costs not disclosed.

Taxation Policy Impact

Effective tax rate resulted in INR 15.8 Cr tax expense for H1 FY26 on PBT of INR 67.1 Cr (~23.5%).

⚠️ Risk Analysis

Key Uncertainties

Regulatory non-compliance risk could trigger product bans or penalties; 180-day exclusivity periods for generics create revenue cliffs if new products aren't launched.